CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive XXXX .

@entity632 @entity1667 @entity1 @entity900 @entity786 @entity2879 @entity2592 @entity177 @entity1891 @entity1893 @entity617
The purpose of the study was to compare conventional @entity786 / @entity632 / @entity1891 / @entity617 (CHOP) chemotherapy with CHOP (3 courses) plus @entity2879 / @entity1667 /high-dose @entity2592 / @entity900 (ESHAP), high-dose therapy (HDT), and autologous peripheral blood progenitor cell transplantation (PBPCT) as front-line treatment for poor-prognosis aggressive @entity1893 ( @entity1893 ). Between May 1, 1995, and April 30, 1998, 58 @entity1 , aged 15-55 years, newly diagnosed with poor-prognosis aggressive @entity1893 (category F-H by the Working Formulation) were enrolled. According to the age-adjusted international prognostic index, 65% of the @entity1 were high-risk cases and 35% made up the high-intermediate group. After 3 courses of CHOP, 25 of 48 @entity1 were randomized to continue with CHOP, and 23 were randomized to receive 2-4 cycles of ESHAP followed by HDT and PBPCT. There was no significant difference in the rate of complete remission between the two groups (36%, 95% confidence interval [CI]: 18%-57% in CHOP vs. 43%, 95% CI: 23%-65% in ESHAP/HDT) (P = 0.77). With a median follow-up duration of 39 months, the 4-year @entity177 ( @entity177 ) was superior in the ESHAP/HDT group (38%, 95% CI: 18%-58% vs. 15%, 95% CI: 4%-32%) (P = 0.04). The disease-free survival was marginally different in favor of the ESHAP/HDT arm (90%, 95% CI: 47%-98% vs. 37%, 95% CI: 7%-69%) (P = 0.06). The 4-year overall survival between the two treatment arms was comparable (51%, 95% CI: 28%-70% for ESHAP/HDT vs. 30%, 95% CI: 13%-48% for CHOP) (P = 0.25). Treatment-related mortalities were not significantly different between both groups (17%, 95% CI: 5%-39% for ESHAP/HDT vs. 8%, 95% CI: 1%-26% for CHOP) (P = 0.41). However, only 61% of the @entity1 assigned to the ESHAP/HDT arm underwent HDT and PBPCT. As compared with CHOP, the corporate regimen of CHOP/ESHAP/HDT seems to improve the @entity177 in @entity1 with newly diagnosed, poor-prognosis aggressive @entity1893 .
